title: Reboxetine in clinical practice: a review.
abstract: Reboxetine is a selective noradrenaline reuptake inhibitor (NaRI), the first drug of a new antidepressant class. Reboxetine has been approved for the treatment of Major Depression in many European countries, but the application for approval was rejected in the United States. It has been found useful in Narcolepsy, ADHD, Panic Attack Disorder, treatment of depression in patients with Parkinson' s Disease. Moreover reboxetine has been proposed as an effective and safe therapeutic option for Cocaine Dependence Disorder. Despite a large number of studies have documented that reboxetine was equally effective in treating major depressive illness compared to other antidepressants, recent reports argue reboxetine to be ineffective and potentially harmful for the treatment of acute depression. Aim of the present review is to summarize and discuss the last literature findings, comparing risks and benefits of reboxetine usage in everyday clinical practice.
authors.affiliation: Department of Neuroscience and Imaging, "G. D'Annunzio" University of Chieti, Italy. g.sepede@unich.it
authors.forename: G
authors.initials: G
authors.lastname: Sepede
authors.forename: M
authors.initials: M
authors.lastname: Corbo
authors.forename: F
authors.initials: F
authors.lastname: Fiori
authors.forename: G
authors.initials: G
authors.lastname: Martinotti
mesh_terms: D000928:Antidepressive Agents / Q000627:therapeutic use*; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy; D003863:Depression / Q000188:drug therapy; D006801:Humans; D009025:Morpholines / Q000627:therapeutic use*; D000077593:Reboxetine; D012893:Sleep Wake Disorders / Q000188:drug therapy
chemical_list: D000928:Antidepressive Agents; D009025:Morpholines; D000077593:Reboxetine